Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WINDLAS BIOTECH Gains 6%; BSE HEALTHCARE Index Down 1.0%
Tue, 29 Oct 12:40

WINDLAS BIOTECH Gains 6%; BSE HEALTHCARE Index Down 1.0%Image source: alexsl/www.istockphoto.com

WINDLAS BIOTECH share price has zoomed 6% and is presently trading at Rs 990.9.

Meanwhile, the BSE HEALTHCARE index is at 43,003.5 (down 1.0%).

Among the top gainers in the BSE HEALTHCARE index today are CAPLIN POINT (up 2.7%) and MAX HEALTHCARE INSTITUTE (up 2.0%).

Glenmark Pharma (down 3.5%) and Dr. Reddys (down 3.2%) are among the top losers today.

Over the last one year, WINDLAS BIOTECH has moved up from Rs 322.1 to Rs 990.9, registering a gain of Rs 668.8 (up 207.7%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,318.2 to 43,003.5, registering a gain of 57.4% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 225.9%), Glenmark Pharma (up 120.2%) and SUVEN PHARMACEUTICALS (up 118.7%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 79,897.7 (down 0.1%).

The top losers among the BSE Sensex today are Tata Motors (down 3.7%) and Maruti Suzuki (down 2.0%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.

In the meantime, NSE Nifty is at 24,287.7 (down 0.2%). Tata Motors and IOC are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,049.1 to 79,897.7, registering a gain of 15,848.6 points (up 24.7%).

WINDLAS BIOTECH Financial Update...

WINDLAS BIOTECH net profit grew 11.7% YoY to Rs 135 million for the quarter ended June 2024, compared to a profit of Rs 121 million a year ago. Net sales rose 21.0% to Rs 1,752 million during the period as against Rs 1,448 million in April-June 2023.

For the year ended March 2024, WINDLAS BIOTECH reported 36.5% increase in net profit to Rs 582 million compared to net profit of Rs 426 million during FY23. Revenue of the company grew 23.0% to Rs 6,310 million during FY24.

The current Price to earnings ratio of WINDLAS BIOTECH, based on rolling 12 month earnings, stands at 34.7.


Equitymaster requests your view! Post a comment on "WINDLAS BIOTECH Gains 6%; BSE HEALTHCARE Index Down 1.0%". Click here!